Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and PK of [14C]-BIBF 1120 in Healthy Males
NCT02182154Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2005
- Primary completion
- Nov 2005
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Primary endpoints: [14C]-radioactivity in plasma and whole blood (C Blood cells/C plasma ratio), [14C]-radioactivity in urine and 20 more. Started Oct 2005; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02182154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182154.